Clinical

Phase I/II/III analysis and reporting is a key function of MBDD and is where most added value is produced by modeling & trial simulation in the learn -confirm paradigm of drug development. Most go/no-go decisions are taken early on Phase I or Phase IIa, proof of concept. DMC scientists have expertise with drug - disease modeling geared to clinical phases.

Bioequivalence

Dynakin/ DMC has extensive experience with bioequivalence problem solving employing population PK methods. This rare capability permits a more thorough understanding of the overall equivalence that may exist across separate studies performed by the sponsor but cannot be resolved by classical NCA bioequivalence methods.

Post marketing

Phase IV studies or post marketing studies have regularly being part of DMC's external collaborations, often in close contact with patient organizations, clinics.